Company intelligence / Profile preview

Spero Technologies

Cambridge, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Spero Therapeutics has advanced tebipenem HBr, an investigational oral carbapenem antibiotic for complicated urinary tract infections including pyelonephritis, through a successful Phase 3 trial that met its primary endpoint early. This positions tebipenem HBr to potentially become the first oral carbapenem available in the US for these indications. The company also maintains a pipeline of preclinical assets targeting rare and drug-resistant bacterial infections.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

GSK (co-development/partnership on tebipenem HBr)Roche (antibiotics partnership on earlier program)

Beyond the preview

Go deeper on Spero Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spero Technologies.

Explore the full profile